EZZ Life Science Holdings Full Year 2023 Earnings: EPS: AU$0.085 (vs AU$0.031 in FY 2022)

EZZ Life Science Holdings (ASX:EZZ) Full Year 2023 Results

Key Financial Results

• Revenue: AU$37.4m (up 149% from FY 2022).
• Net income: AU$3.63m (up 177% from FY 2022).
• Profit margin: 9.7% (up from 8.7% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: AU$0.085 (up from AU$0.031 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

EZZ Life Science Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Global Life Sciences industry.

Performance of the market in Australia.

The company's shares are down 18% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for EZZ Life Science Holdings that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.